Schlenk RF - Search Results

1

Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).

Voso MT, Martin S, Hohaus S, Abdallah A, Schlenk RF, Ho AD, Haas R. Voso MT, et al. Among authors: schlenk rf. Bone Marrow Transplant. 2000 May;25(9):957-64. doi: 10.1038/sj.bmt.1702336. Bone Marrow Transplant. 2000. PMID: 10800063

2

Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone.

Schlenk RF, Döhner H, Pförsich M, Benner A, Fischer K, Hartmann F, Fischer JT, Weber W, Gunzer U, Pralle H, Haas R. Schlenk RF, et al. Br J Haematol. 1997 Nov;99(2):386-93. doi: 10.1046/j.1365-2141.1997.3933207.x. Br J Haematol. 1997. PMID: 9375760 Free article.

3

Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content.

Voso MT, Hohaus S, Moos M, Pförsich M, Cremer FW, Schlenk RF, Martin S, Hegenbart U, Goldschmidt H, Haas R. Voso MT, et al. Among authors: schlenk rf. Br J Haematol. 1999 Feb;104(2):382-91. doi: 10.1046/j.1365-2141.1999.01171.x. Br J Haematol. 1999. PMID: 10050723 Free article.

4

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.

Hohaus S, Funk L, Martin S, Schlenk RF, Abdallah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiss A, Fersis N, Kaul S, Wallwiener D, Bastert G, Haas R. Hohaus S, et al. Among authors: schlenk rf. Br J Cancer. 1999 Mar;79(9-10):1500-7. doi: 10.1038/sj.bjc.6690239. Br J Cancer. 1999. PMID: 10188897 Free PMC article.

5

Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer.

Hohaus S, Martin S, Schneeweiss A, Voso MT, Schlenk RF, Wallwiener D, Bastert G, Haas R. Hohaus S, et al. Among authors: schlenk rf. Cancer Chemother Pharmacol. 1999;44 Suppl:S13-7. doi: 10.1007/s002800051110. Cancer Chemother Pharmacol. 1999. PMID: 10602904 Clinical Trial.

6

Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients.

Seute A, Sinn HP, Schlenk RF, Emig R, Wallwiener D, Grischke EM, Hohaus S, Döhner H, Haas R, Bentz M. Seute A, et al. Among authors: schlenk rf. Int J Cancer. 2001 Jul 1;93(1):80-4. doi: 10.1002/ijc.1296. Int J Cancer. 2001. PMID: 11391625 Free article.

7

Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.

Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gabler A, Haas R, Ho AD, Trümper L, Döhner H. Schlenk RF, et al. Leukemia. 2002 Apr;16(4):581-6. doi: 10.1038/sj.leu.2402423. Leukemia. 2002. PMID: 11960336 Clinical Trial.

8

Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.

Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, Hensel M, Fröhling S, Döhner K, Haas R, Döhner H; AML Study Group Ulm (AMLSG ULM). Schlenk RF, et al. Leukemia. 2003 Aug;17(8):1521-8. doi: 10.1038/sj.leu.2403009. Leukemia. 2003. PMID: 12886238 Clinical Trial.

9

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.

Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W, Götze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B, Döhner K, Haas R, Döhner H; AML Study Group Ulm. Schlenk RF, et al. Leukemia. 2004 Nov;18(11):1798-803. doi: 10.1038/sj.leu.2403528. Leukemia. 2004. PMID: 15385923 Clinical Trial.

10

HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.

Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A; CIBMTR Acute Leukemia Working Committee. Schlenk RF, et al. Biol Blood Marrow Transplant. 2008 Feb;14(2):187-96. doi: 10.1016/j.bbmt.2007.10.006. Epub 2007 Dec 20. Biol Blood Marrow Transplant. 2008. PMID: 18215779 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

257 results

Search Page